CEO Moshe Mizrahy’s Group Offers to Take InMode Private at $16.20 Per Share
Board forms special committee to evaluate the offer.
/ 237 items
#XY Event-Driven Stocks↓
Absci Rockets on Positive ABS-201 Data and $100M Financing Backed by Eli Lilly
Eli Lilly participates in Absci’s $100M equity offering to fund ABS-201, a novel prolactin receptor antibody showing strong safety in Phase 1 for pattern hair loss and endometriosis.
Sangamo Therapeutics Files for Chapter 11 Bankruptcy, Strikes Asset Deals with Eli Lilly and Astellas
The deals cover key gene therapy platforms and the Fabry disease program in a court-supervised auction.
Zcash Miner Fortitude to List on Nasdaq Through Merger with HeartSciences
The combined company will list on Nasdaq under the ticker TUDE in H2 2026.
Serapha Bio to Go Public via Merger with Boundless Bio, Raising $230 Million
Boundless Bio and Serapha Bio announce a merger and $230 million private placement. The combined company will advance SERP-01, a base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).
MacroGenics to Receive $24.5 Million Milestone Payment from Sanofi Following FDA Approval of TZIELD for Stage 3 Type 1 Diabetes
MacroGenics receives $24.5 million from Sanofi after FDA expands TZIELD approval to children aged 8-17 with newly diagnosed stage 3 Type 1 diabetes.